Anthem Biosciences Limited (NSE:ANTHEM)
India · Delayed Price · Currency is INR 822.70
-23.25 (-2.75%)
At close: Aug 22, 2025, 3:30 PM IST
Anthem Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 20,462 | 18,446 | 14,194 | 10,569 | 12,313 | 11,032 |
Other Revenue | 58.37 | 58.37 | 8 | 9.82 | 95.09 | 21.77 |
| 20,520 | 18,504 | 14,202 | 10,579 | 12,408 | 11,054 | |
Revenue Growth (YoY) | 40.13% | 30.29% | 34.24% | -14.74% | 12.24% | - |
Cost of Revenue | 8,658 | 7,815 | 6,254 | 3,574 | 4,270 | 4,637 |
Gross Profit | 11,862 | 10,689 | 7,948 | 7,005 | 8,137 | 6,417 |
Selling, General & Admin | 2,869 | 2,623 | 1,844 | 1,540 | 1,379 | 1,426 |
Other Operating Expenses | 1,513 | 1,292 | 1,039 | 1,103 | 982.96 | 843.76 |
Operating Expenses | 5,353 | 4,809 | 3,702 | 3,280 | 2,940 | 2,893 |
Operating Income | 6,508 | 5,880 | 4,246 | 3,725 | 5,197 | 3,524 |
Interest Expense | -79.22 | -100.17 | -92.76 | -82.01 | -115.6 | -159.99 |
Interest & Investment Income | 647 | 647 | 408.62 | 290.99 | 95.76 | 8.45 |
Currency Exchange Gain (Loss) | 73.42 | 73.42 | 146.18 | 128.89 | 133.26 | 159.71 |
Other Non Operating Income (Expenses) | 30.8 | -2.78 | -1.86 | 223.59 | 16.62 | 56.24 |
EBT Excluding Unusual Items | 7,180 | 6,498 | 4,706 | 4,286 | 5,327 | 3,588 |
Gain (Loss) on Sale of Investments | 75.78 | 75.78 | 71.8 | 68.97 | 135.99 | 69.47 |
Gain (Loss) on Sale of Assets | -4.64 | -4.64 | -4.35 | -0.03 | -1.84 | -1.87 |
Other Unusual Items | - | - | - | 618.02 | - | - |
Pretax Income | 7,251 | 6,569 | 4,773 | 4,973 | 5,461 | 3,656 |
Income Tax Expense | 2,205 | 2,056 | 1,100 | 1,121 | 1,406 | 942.72 |
Net Income | 5,047 | 4,513 | 3,673 | 3,852 | 4,055 | 2,713 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.01 |
Net Income to Common | 5,047 | 4,513 | 3,673 | 3,852 | 4,055 | 2,713 |
Net Income Growth | 35.98% | 22.86% | -4.64% | -5.02% | 49.48% | - |
Shares Outstanding (Basic) | 559 | 559 | 567 | 570 | 570 | 547 |
Shares Outstanding (Diluted) | 562 | 562 | 567 | 570 | 570 | 547 |
Shares Change (YoY) | -0.48% | -0.96% | -0.61% | - | 4.33% | - |
EPS (Basic) | 9.03 | 8.07 | 6.48 | 6.75 | 7.11 | 4.96 |
EPS (Diluted) | 8.99 | 8.04 | 6.48 | 6.75 | 7.11 | 4.96 |
EPS Growth | 36.71% | 24.11% | -4.03% | -5.04% | 43.27% | - |
Free Cash Flow | - | 1,038 | -1,499 | 1,171 | 1,771 | 1,618 |
Free Cash Flow Per Share | - | 1.85 | -2.64 | 2.05 | 3.10 | 2.96 |
Gross Margin | 57.81% | 57.77% | 55.96% | 66.21% | 65.58% | 58.05% |
Operating Margin | 31.72% | 31.78% | 29.89% | 35.21% | 41.89% | 31.88% |
Profit Margin | 24.59% | 24.39% | 25.86% | 36.41% | 32.68% | 24.54% |
Free Cash Flow Margin | - | 5.61% | -10.55% | 11.06% | 14.27% | 14.64% |
EBITDA | 7,405 | 6,759 | 5,050 | 4,358 | 5,763 | 4,134 |
EBITDA Margin | 36.09% | 36.53% | 35.56% | 41.19% | 46.45% | 37.40% |
D&A For EBITDA | 897.22 | 878.75 | 804.85 | 633.27 | 566.06 | 610.8 |
EBIT | 6,508 | 5,880 | 4,246 | 3,725 | 5,197 | 3,524 |
EBIT Margin | 31.72% | 31.78% | 29.89% | 35.21% | 41.89% | 31.88% |
Effective Tax Rate | 30.40% | 31.30% | 23.05% | 22.54% | 25.74% | 25.79% |
Revenue as Reported | 21,353 | 19,303 | 14,831 | 11,340 | 12,802 | 11,404 |
Advertising Expenses | - | 15.62 | 10.62 | 5.35 | 1.17 | 1.18 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.